The mechanisms of the increase in serum KL-6 levels in various fibrotic lung diseases are thought to be due to an overexpression of KL-6 by regenerating alveolar type II pneumocytes, and/or due to an increased permeability following disintegration of the alveolar-vessel barrier [17,18]. This evidence concerns the gene MUC1 and lung disorder.